Overview

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Atorvastatin
Atorvastatin Calcium
Fenofibrate
Rosuvastatin Calcium
Simvastatin